Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
CORT Catalyst Timeline
Dated clinical, regulatory and corporate events for Corcept Therapeutics Incorporated
Catalyst Timeline
Dated clinical, regulatory & corporate events for Corcept Therapeutics Incorporated
Upcoming catalysts 2
Event history 50
Past FDA Catalysts and PDUFA Decisions
How CORT actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-11-03 | miricorilant | Phase 2b data readout | Phase 2b |
Drug Pipeline Intelligence
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Hypercortisolism Products | |||
| Lifyorli |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dazucorilant Small MoleculesNCT05407324 | Amyotrophic Lateral Sclerosis | Phase 2 | ACTIVE NOT_RECRUITING | 279 | Nov 1, 2027 | ||||||
| Nenocorilant BiologicsNCT07276373 | Neoplasms | Phase 1/2 | RECRUITING | 50 | Jan 1, 2027 | ||||||
| Relacorilant Small MoleculesMarketedNCT05257408 | Ovarian Neoplasm | Approved | ACTIVE NOT_RECRUITING | 381 | Dec 1, 2026 | ||||||
| Relacorilant Small MoleculesMarketedNCT07259317 | Adenocarcinoma | Approved | RECRUITING | 80 | Sep 1, 2027 | ||||||
| Relacorilant Small MoleculesMarketedNCT06906341 | Ovarian Cancer | Approved | RECRUITING | 270 | Aug 1, 2028 | ||||||
| Relacorilant Small MoleculesNCT03604198 | Cushing Syndrome | NDA/BLA | ACTIVE NOT_RECRUITING | 307 | Dec 1, 2026 | ||||||
| Miricorilant Small MoleculesCompletedNCT06947304 | Nonalcoholic Steatohepatitis (NASH) | Phase 2 | COMPLETED | 268 | Sep 15, 2026 | ||||||
| Miricorilant Small MoleculesCompletedNCT05712265 | Antipsychotic Induced Weight Gain | Phase 2 | COMPLETED | 97 | Feb 23, 2023 | ||||||
| Miricorlilant Small MoleculesCompletedNCT04524403 | Antipsychotic-induced Weight Gain (AIWG) | Phase 2 | COMPLETED | 150 | Aug 25, 2022 | ||||||
| Miricorilant Small MoleculesCompletedNCT05553470 | Non-alcoholic Steatohepatitis (NASH) | Phase 1 | COMPLETED | 19 | Sep 13, 2024 | ||||||
| Miricorilant Treatment A Small MoleculesCompletedNCT07240116 | Undisclosed | Phase 1 | COMPLETED | 18 | Mar 3, 2026 | ||||||
| CORT118335 Small MoleculesCompletedNCT03877562 | Antipsychotic-induced Weight Gain | Phase 1 | COMPLETED | 96 | Mar 25, 2020 | ||||||
| Dazucorilant Small MoleculesCompletedNCT06928779 | Hepatic Impairment | Phase 1 | COMPLETED | 19 | Dec 9, 2024 | ||||||
| CORT113176 Small MoleculesCompletedNCT04994743 | Undisclosed | Phase 1 | COMPLETED | 22 | Sep 30, 2021 | ||||||
| CORT125236 Small MoleculesCompletedNCT05003713 | Undisclosed | Phase 1 | COMPLETED | 82 | Feb 3, 2023 | ||||||
| Relacorilant Small MoleculesNot countedNCT04308590 | Hypercortisolism | Phase 3 | COMPLETED | 137 | Sep 19, 2024 | ||||||
| Relacorilant Small MoleculesMarketedNCT03776812 | Recurrent Ovarian Cancer | Approved | COMPLETED | 178 | Jul 12, 2023 | ||||||
| Relacorilant Small MoleculesNot countedNCT02762981 | Solid Tumors | Phase 1/2 | COMPLETED | 85 | Sep 12, 2020 | ||||||
| Relacorilant Small MoleculesNot countedNCT06094725 | Hepatic Impairment | Phase 1 | COMPLETED | 30 | Dec 14, 2020 | ||||||
| Relacorilant Small MoleculesNot countedNCT04373265 | Adrenocortical Carcinoma | Phase 1 | COMPLETED | 15 | Jan 12, 2024 | ||||||
| Relacorilant Small MoleculesNot countedNCT03674814 | Prostate Cancer | Phase 1 | COMPLETED | 42 | Jun 10, 2024 | ||||||
| CORT125134 Small MoleculesCompletedNCT02804750 | Cushing's Syndrome | NDA/BLA | COMPLETED | 35 | Sep 1, 2018 | ||||||
| CORT125281 Small MoleculesCompletedNCT03335956 | Undisclosed | Phase 1 | COMPLETED | 48 | Jun 25, 2018 | ||||||
| CORT125329 lipid formulation Small MoleculesCompletedNCT04672512 | Undisclosed | Phase 1 | COMPLETED | 115 | Jan 17, 2022 | ||||||
| Mifepristone Small MoleculesMarketedNCT00936741 | Cushing's Syndrome | Approved | COMPLETED | 80 | Sep 1, 2012 |
Clinical Trial Results
Readouts, endpoints and source filings for every CORT program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Lifyorli | platinum-resistant ovarian cancer | Phase 2 | 2026-10-26 | median progression free survival: 7.2 months; objective response rate: 59%; median progression free survival bevacizumab naive: 8.1 months; objective response rate bevacizumab naive: 66%; overall survival 6 months: 91%Read More | Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian CancerRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| WILSON JAMES NDirector | Sell | -2,191 1,052,352 held | $71.80 | 11/13/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CORT
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 8 % (35.6 %) | 172.84 M | 1.50 M |
Ownership Trends
CORT Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How CORT ranks across every disease it competes in
CORT News
ESMO Rare Cancers Publishes Case Report Detailing Eight-Year Response to Relacorilant Plus Nab-Paclitaxel in Metastatic Vulvar Cancer
Corcept Therapeutics announced a peer-reviewed case report detailing an eight-year response to relacorilant plus nab-paclitaxel in a patient with metastatic vulvar cancer. The patient achieved a duration of response exceeding 105 months, significantly longer than previous treatments. This case highlights the potential benefits of glucocorticoid receptor antagonism in treating challenging cancers.
Read more →Corcept Therapeutics Announces Third Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported a strong third quarter with revenues of $340.5 million, a 64% increase from the previous year. The company reiterated its 2026 revenue guidance of $1.1 to $1.2 billion. Notably, Lifyorli's rapid adoption in ovarian cancer treatment was highlighted, with over 2,300 patients treated since its launch.
Read more →Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics will announce its third quarter financial results on November 3, 2026. The company will also provide a corporate update and host a conference call at 5:00 p.m. ET. Corcept has a strong focus on cortisol modulation and has recently introduced Lifyorli for platinum-resistant ovarian cancer.
Read more →Corcept Reports Positive Results from Phase 2 BELLA Trial of Lifyorli® Combined with Nab-Paclitaxel and Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer
Corcept Therapeutics announced positive results from its Phase 2 BELLA trial, where Lifyorli combined with nab-paclitaxel and bevacizumab showed significant improvements in progression-free survival and objective response rate in patients with platinum-resistant ovarian cancer. The median progression-free survival was 7.2 months, with 59% achieving an objective response. Results were particularly favorable for patients who had not previously received bevacizumab.
Read more →2026 ADA/EASD Consensus Report Recommends Screening for Hypercortisolism in Patients with Difficult-to-Control Type 2 Diabetes
The 2026 ADA/EASD consensus report recommends screening for hypercortisolism in adults with difficult-to-control type 2 diabetes. This recommendation is based on Corcept's CATALYST study, which showed that cortisol-directed therapy with mifepristone significantly reduced HbA1c levels. The report highlights the importance of identifying treatable causes of hyperglycemia in these patients.
Read more →Corcept Announces Planned Leadership Transition
Corcept Therapeutics has announced the retirement of Sean Maduck, the President of its Endocrinology division. Justin Gunn will take over his responsibilities starting in October. This leadership change is part of the company's ongoing strategy to enhance its focus on developing treatments for various severe disorders.
Read more →Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)
Corcept Therapeutics announced that the CHMP has recommended the approval of relacorilant for marketing authorization in the European Union. This recommendation is a significant step towards making the drug available to patients in Europe. The approval could enhance Corcept's market presence and support its mission to treat severe disorders.
Read more →Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease
The presentation titled 'Prevalence of Hypercortisolism in Individuals With Resistant Hypertension and Cardiovascular Disease' was delivered by Dr. Pam R. Taub at the American Society for Preventive Cardiology Congress on July 31, 2026. This research highlights the prevalence of hypercortisolism in patients facing resistant hypertension and cardiovascular issues, suggesting important clinical implications.
Read more →Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
Corcept Therapeutics reported strong financial results for the second quarter of 2026, highlighting the success of its oncology and Cushing's syndrome segments. The company continues to focus on developing medications that modulate cortisol effects for various severe disorders. This positive performance reflects the company's growth and market presence.
Read more →Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
Corcept Therapeutics has announced the date for its second quarter financial results report, set for July 29, 2026. The company will provide a corporate update during this time and host a conference call at 5:00 p.m. Eastern Time. Participants are required to register in advance to receive access details.
Read more →Prevalence of Endogenous Hypercortisolism in Individuals With Resistant Hypertension Stratified by Kidney Function: Results From the MOMENTUM Study
The MOMENTUM study, presented at the 10th Annual Heart in Diabetes CME Conference, explores the prevalence of endogenous hypercortisolism in individuals with resistant hypertension, stratified by kidney function. The findings aim to enhance understanding of this condition and its implications for treatment. The presentation was made by Dr. Ralph A. DeFronzo.
Read more →Efficacy and Safety of Relacorilant + Nab-paclitaxel in Patients Aged ≥65 Years With Platinum-resistant Ovarian Cancer (PROC) in the Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10)
The Phase 3 ROSELLA Study (GOG-3073, ENGOT-OV72, APGOT-Ov10) presented findings on the efficacy and safety of Relacorilant combined with Nab-paclitaxel in treating platinum-resistant ovarian cancer in patients aged 65 and older. The results were shared at the European Society for Medical Oncology Gynaecological Cancers Annual Congress. The study's focus on older patients addresses a significant gap in treatment options.
Read more →Real-World Comparative Effectiveness of Nab-paclitaxel and Standard of Care Chemotherapies in Patients With Platinum-Resistant Ovarian Cancer (COMPASS 2.0)
The COMPASS 2.0 study evaluates the comparative effectiveness of nab-paclitaxel versus standard chemotherapy in patients with platinum-resistant ovarian cancer. Presented by Dr. Mark S. Shahin at the European Society for Medical Oncology Gynaecological Cancers Annual Congress, the findings contribute valuable insights into treatment options for this challenging patient population.
Read more →Corcept Resubmits New Drug Application for Relacorilant as a Treatment for Patients with Cushing’s Syndrome
Corcept Therapeutics has resubmitted its New Drug Application (NDA) for relacorilant, intended for the treatment of Cushing's syndrome. This resubmission follows previous interactions with the FDA. The company aims to address the needs of patients suffering from this condition with its investigational therapy.
Read more →Endogenous Hypercortisolism in Individuals With Resistant Hypertension and Difficult-to-Control Type 2 Diabetes: Results From Two Large, Prospective Studies
The article discusses the presentation of results from two large prospective studies on endogenous hypercortisolism in patients with resistant hypertension and difficult-to-control type 2 diabetes. The findings were presented by Dr. Ralph DeFronzo at the Endocrine Society Annual Meeting in Chicago. This research highlights important health implications for managing these conditions.
Read more →Characterization of Individuals With Resistant Hypertension and Post-Dexamethasone Suppression Test Cortisol 1.8 μg/dL: Results From the MOMENTUM Study
The MOMENTUM Study results were presented at the Endocrine Society Annual Meeting, highlighting the characterization of individuals with resistant hypertension and their cortisol levels post-dexamethasone suppression test. The findings may provide valuable insights into managing this condition. The study emphasizes the importance of cortisol measurements in understanding hypertension resistance.
Read more →High Prevalence of Endogenous Hypercortisolism in Patients With Type 2 Diabetes and Resistant Hypertension: Results From the MOMENTUM Study
The MOMENTUM study presented by Dr. Guillermo Umpierrez at the American Diabetes Association Scientific Sessions revealed a high prevalence of endogenous hypercortisolism in patients with type 2 diabetes and resistant hypertension. This research adds important knowledge to the understanding of the interplay between these conditions. The findings were shared at a prominent scientific event in New Orleans.
Read more →Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs
The presentation titled 'Effects of Mifepristone in People With Difficult-to-Control T2D and Hypercortisolism on GLP-1 RAs' was delivered by Dr. Lance A. Sloan at the American Diabetes Association Scientific Sessions on June 6, 2026. It discusses the impact of mifepristone on patients struggling with type 2 diabetes and hypercortisolism, particularly in relation to GLP-1 receptor agonists.
Read more →Corcept Presents New Data at ADA: Improved Outcomes in Patients Receiving a GLP-1 with Difficult-to-Control Type 2 Diabetes and Hypercortisolism Treated with Korlym®
Corcept has presented new data at the ADA conference regarding the outcomes of patients with difficult-to-control Type 2 diabetes and hypercortisolism treated with Korlym®. The findings suggest improvements in patient outcomes when Korlym® is used alongside GLP-1 receptor agonists. Further details on the data and implications for treatment were highlighted during the presentation.
Read more →SYNERGY: A Phase 1b/2 Study of Nenocorilant, a Selective Glucocorticoid Receptor Antagonist, Plus Nivolumab in Patients With Advanced Solid Malignancies
The SYNERGY study investigates the efficacy of nenocorilant combined with nivolumab in patients with advanced solid tumors. Presented by Dr. Omid Hamid at the American Society of Clinical Oncology Annual Meeting, this Phase 1b/2 trial aims to provide insights into this innovative treatment approach. The findings may contribute to new therapeutic strategies in oncology.
Read more →